Triple-negative breast cancer recurrence after a mastectomy is one of the most aggressive types of cancer. It's harder to treat than other types of breast cancer because it lacks the three most ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

High grade tumors: Most cases are high grade tumors; very few are low grade and those are more conservative than TNBC. Early recurrence: The risk of recurrence in TNBC peaks within the first 3 ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the ...

Patient-derived xenografts (PDX) may accurately predict early recurrence and survival outcomes in triple negative breast cancer (TNBC), offering a potential tool for tailoring treatment strategies ...

This reduces the risk of local recurrence significantly. Newer targeted therapies have emerged despite TNBC’s lack of the three common receptors. These include PARP inhibitors for patients with ...

ctDNA was most frequently detected within six months post-treatment, aligning with TNBC's early recurrence pattern. Exploratory analysis suggested longer recurrence-free intervals in patients with low ...

TNBC is one of the most aggressive forms of ... “I don’t think about recurrence every single day.” That’s an important goal, according to Amit Kumar, chairman and chief executive officer ...

A total of 147 (8%) were ctDNA-positive (n=135 with TNBC; n=12 with BRCA-mutated HR-positive BC). Of those patients who had ctDNA detected, 107 either had radiologic recurrence when DNA was ...

often facing a higher risk of recurrence and lower survival rates. However, a recent breakthrough in research and treatment is bringing newfound hope to those affected by TNBC. Advances in ...

In early-stage TNBC, carboplatin is already being incorporated ... Events included disease progression, local or distant recurrence, occurrence of a second primary cancer, inoperable status ...